Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty

NCT ID: NCT01683071

Last Updated: 2020-12-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 297 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-09-30
• Study Completion Date: 2013-12-31

Brief Summary

The primary objectives of Part 1 are to (1) evaluate three dose levels of liposome bupivacaine versus placebo with respect to the magnitude and duration of the analgesic effect achieved following single dose injection femoral nerve block with liposome bupivacaine, and (2) select a single therapeutic dose of liposome bupivacaine from the three dose levels to be tested in Part 2.

Part 2: The primary objective of Part 2 is to compare the magnitude and duration of the analgesic effect of single injection femoral nerve block of a single dose level of liposome bupivacaine (selected from Part 1) with placebo (preservative-free normal saline).

Detailed Description

This is a Phase 2/3, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study in subjects undergoing primary unilateral total knee arthroplasty (TKA) under general or spinal anesthesia. Note: Bupivacaine cannot be used as the spinal anesthetic.

Part 1 During Part 1 of the study, approximately 100 subjects (25 per treatment arm) will be randomized to receive a single dose injection femoral nerve block with either one of three doses of liposome bupivacaine (67, 133, or 266 mg) or placebo in 20 mL under ultrasound guidance. Preservative-free normal saline will be added to the 67 mg and 133 mg doses of study drug to achieve a volume of 20 mL.

Part 2 In Part 2 of the study, approximately 180 subjects (randomized 1:1, resulting in approximately 90 liposome bupivacaine subjects and 90 placebo subjects) will receive a single dose injection femoral nerve block with the selected dose level of liposome bupivacaine (i.e., 67, 133, or 266 mg) or placebo in 20 mL under ultrasound guidance.

Conditions

Postoperative Pain

Keywords

Total knee arthroplasty; Analgesia; Pain management

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

(Part 1) EXPAREL 67 mg

5 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 15 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively

Group Type: EXPERIMENTAL

EXPAREL 67 mg

Intervention Type: DRUG

5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty

(Part 1) EXPAREL 133 mg

10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively

Group Type: EXPERIMENTAL

EXPAREL 133 mg

Intervention Type: DRUG

10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty

(Part 1) EXPAREL 266 mg

20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively

Group Type: EXPERIMENTAL

EXPAREL 266 mg

Intervention Type: DRUG

20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty

(Part 1) Placebo

20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty

(Part 2) EXPAREL 266 mg

20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively

Group Type: EXPERIMENTAL

EXPAREL 266 mg

Intervention Type: DRUG

20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty

(Part 2) Placebo

20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty

Interventions

Placebo

Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty

Intervention Type: DRUG

EXPAREL 67 mg

5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty

Intervention Type: DRUG

EXPAREL 133 mg

10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty

Intervention Type: DRUG

EXPAREL 266 mg

20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty

Intervention Type: DRUG

Other Intervention Names

Preservative-free normal saline.; Bupivacaine liposome injectable suspension 67 mg/5 mL; Bupivacaine liposome injectable suspension 133 mg/10 mL; Bupivacaine liposome injectable suspension 266 mg/20 mL

Eligibility Criteria

Inclusion Criteria

1. Male or female, >=18 years of age.

2. Scheduled to undergo primary unilateral TKA under general or spinal anesthesia.

3. American Society of Anesthesiologists (ASA) Physical Status 1, 2, or 3.

4. Able to demonstrate motor function by performing a 20-meter walk, unassisted with the optional use of a 4-legged walker, and sensory function by exhibiting sensitivity to cold.

5. Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments.

Exclusion Criteria

1. Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration. Female subjects must be surgically sterile, at least 2 years menopausal, or using an acceptable method of birth control.

If of childbearing potential, must have a documented negative pregnancy test within 24 hours before surgery.

2. Planned concurrent surgical procedure (e.g., bilateral TKA).

3. Use of any of the following medications within the times specified before surgery:

long-acting opioid medication, NSAIDs, aspirin (except for low-dose aspirin used for cardioprotection) or acetaminophen within 3 days, or and any opioid medication within 24 hours.

4. Concurrent painful physical condition or concurrent surgery that may require analgesic treatment (such as an NSAID or opioid) in the postsurgical period for pain that is not strictly related to the surgical site administered study treatment, and which may confound the postsurgical assessments (e.g., significant pain from other joints including the non-index knee joint, chronic neuropathic pain, prior contralateral TKA, concurrent foot surgery).

5. Initiation of treatment with any of the following medications within 1 month of study drug administration or if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective norepinepherine reuptake inhibitors (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®).

6. Current use of systemic glucocorticosteroids within 1 month of enrollment in this study.

7. Body weight < 50 kilograms (110 pounds) or a body mass index ≥ 40 kg/m2.

8. Contraindication to hydromorphone, oxycodone, or bupivacaine.

9. Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.

10. Previous participation in a liposome bupivacaine study.

11. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.

12. Failure to pass the urine drug screen.

13. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, could interfere with study assessments or compliance.

14. Malignancy in the last 2 years, with the exception of non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.

15. Current or historical evidence of any clinically significant disease or condition, especially cardiovascular or neurological conditions that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postsurgical course.

16. Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures.

17. Subjects who are planned to receive Entereg® (alvimopan).

18. Subjects who will receive prophylactic antiemetics or planned postsurgical antiemetics given without regard to the subject's emesis needs.

19. Use of dexmedetomidine HCl (Precedex®) within 3 days of surgery.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pacira Pharmaceuticals, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Erol Onel, MD

Role: STUDY_DIRECTOR

Pacira Pharmaceuticals, Inc

Locations

ACHIEVE CLINICAL RESEARCH LLC 2017 Canyon Road Suite 41

Birmingham, Alabama, United States

HORIZON RESEARCH GROUP INC 3610 Springhill Memorial Dr. N

Mobile, Alabama, United States

Veritas Research, LLC

Mobile, Alabama, United States

SHOALS MEDICAL TRIALS INC. 1300 S Montgomery Ave

Sheffield, Alabama, United States

PHOENIX ORTHOPAEDIC SURGEONS 2525 W. Greenway Road Suite 114

Phoenix, Arizona, United States

ALLIANCE RESEARCH CENTERS 24411 Health Center Drive Suite 350

Laguna Hills, California, United States

ORTHOPADIC SURGERY Loma Linda University Health Care Dept. Pf Orthopaedic Surgery 250 East Caroline Street Suite A

San Bernardino, California, United States

University of California, San Diego

San Diego, California, United States

Ilfeld, Brian (Thornton) UNIVERSITY OF CALIFORNIA, SAN DIEGO 10610 Hunters Glen Drive

San Diego, California, United States

FLORIDA RESEARCH ASSOCIATES, LLC / FLORIDA ORTHOPAEDIC ASSOCIATES 740 W. Plymouth Ave

DeLand, Florida, United States

JACKSON MEMORIAL HOSPITAL UNVERSITY OF MIAMI 1611 Nw. 12th Ave C300

Miami, Florida, United States

PENSACOLA RESEARCH CONSULTANTS,INC 5149 N.9th Avenue Suite 241

Pensacola, Florida, United States

SHERIDAN CLINICAL RESEARCH, INC. 1613 N. Harrison Parkway Building C Suite 200

Sunrise, Florida, United States

PHOENIX CLINICAL RESEARCH,LLC 7171 N. University Drive Suite 100

Tamarac, Florida, United States

UNIVERSITY OF KANSAS HOSPITAL & MEDICAL CENTER Dept. Of Anesthesiology 3901 Rainbow Blvd. Ms 1034

Kansas City, Kansas, United States

BEAUMONT HEALTH SYSTEM 44201 Dequindre Road Suite Pob 120

Troy, Michigan, United States

COOPER UNIVERSITY HOSPITAL 1 Cooper Plaza 202 Dorrance Building

Camden, New Jersey, United States

UNIVERSITY OF MEDICINE AND DENSITRY OF NEW JERSEY/NEW JERSEY MEDICAL SCHOOL 185 South Orange Ave. Department of Anesthesiology - MSB E538

Newark, New Jersey, United States

NORTHERN WESTCHESTER HOSPTIAL Department Of Clinical Trials 400 East Main St.

Mount Kisco, New York, United States

ST. LUKE-ROOSEVELT HOSPITAL CENTER Dept. Of Anesthesiology 1111 Amsterdam Ave. Travis Bld. 7

New York, New York, United States

INSALL-SCOTT-KELLY INSTITUTE 210 East 64th Street

New York, New York, United States

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Department Of Anesthesiology 101 Manning Drive N0021, Cb 7010

Chapel Hill, North Carolina, United States

CLEVELAND CLINIC FAIRVIEW HOSPTIAL 1801 Lorain Avenue

Cleveland, Ohio, United States

CLEVELAND CLINIC 9500 Euclid Ave P-77

Cleveland, Ohio, United States

PENN STATE MILTON S. HERSHEY MEDICAL CENTER H187,500 University Drive

Hershey, Pennsylvania, United States

THOMAS JEFFERSON UNIVERSITY Dept. Of Anesthesiology 111 S. 11th Street Suite G 8490

Philadelphia, Pennsylvania, United States

UPMC PRESBYTERIAN SHADYSIDE/ DEPT. OF ANESTHESIOLOGY POSNER PAIN CENTER 532 South Aiken Avenue Suite 407

Pittsburgh, Pennsylvania, United States

UNIVERSITY OF TEXAS MEDICAL BRANCH Dept. Chairman, Orthopedic Surgery & Rehabilitation 2.316 Rebecca Sealy Hospital 301 University Blvd.

Galveston, Texas, United States

RESEARCH CONCEPTS,GP LLC 921 Gessner Rd. Anesthesia Dept., Classroom F

Houston, Texas, United States

CHRISTUS ST. JOHN HOSPITAL 18300 St. John Dr., 2nd Floor, Surgery

Nassau Bay, Texas, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

402-C-323

Identifier Type: -

Identifier Source: org_study_id